Supernus Pharma (SUPN) Misses Q4 EPS by 6c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.27, $0.06 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $174.16 million versus the consensus estimate of $150.24 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Take-Two Interactive Software: GTA VI launches November 19, 2026 for PS5 and Xbox series X|S at $79.99
• Global S&P Futures mixed in premarket